AU2010260585B2 - Compositions and methods for treatment of Multiple Sclerosis - Google Patents

Compositions and methods for treatment of Multiple Sclerosis Download PDF

Info

Publication number
AU2010260585B2
AU2010260585B2 AU2010260585A AU2010260585A AU2010260585B2 AU 2010260585 B2 AU2010260585 B2 AU 2010260585B2 AU 2010260585 A AU2010260585 A AU 2010260585A AU 2010260585 A AU2010260585 A AU 2010260585A AU 2010260585 B2 AU2010260585 B2 AU 2010260585B2
Authority
AU
Australia
Prior art keywords
multiple sclerosis
treatment
microparticle
mis416
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010260585A
Other languages
English (en)
Other versions
AU2010260585A1 (en
AU2010260585A8 (en
Inventor
Frank B. Gelder
Gillian Alison Webster
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innate Immunotherapeutics Ltd
Original Assignee
Innate Immunotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Immunotherapeutics Ltd filed Critical Innate Immunotherapeutics Ltd
Publication of AU2010260585A1 publication Critical patent/AU2010260585A1/en
Publication of AU2010260585A8 publication Critical patent/AU2010260585A8/en
Application granted granted Critical
Publication of AU2010260585B2 publication Critical patent/AU2010260585B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Fodder In General (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Photographic Developing Apparatuses (AREA)
AU2010260585A 2009-06-16 2010-06-16 Compositions and methods for treatment of Multiple Sclerosis Ceased AU2010260585B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ577731A NZ577731A (en) 2009-06-16 2009-06-16 Compositions and methods for treatment of multiple sclerosis
NZ577731 2009-06-16
PCT/NZ2010/000112 WO2010147484A1 (en) 2009-06-16 2010-06-16 Compositions and methods for treatment of multiple sclerosis

Publications (3)

Publication Number Publication Date
AU2010260585A1 AU2010260585A1 (en) 2012-01-19
AU2010260585A8 AU2010260585A8 (en) 2012-06-14
AU2010260585B2 true AU2010260585B2 (en) 2013-02-21

Family

ID=42646236

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010260585A Ceased AU2010260585B2 (en) 2009-06-16 2010-06-16 Compositions and methods for treatment of Multiple Sclerosis

Country Status (20)

Country Link
US (1) US8389479B2 (enExample)
EP (1) EP2442832B1 (enExample)
JP (1) JP5646617B2 (enExample)
CN (1) CN102458476B (enExample)
AU (1) AU2010260585B2 (enExample)
BR (1) BRPI1009606A2 (enExample)
CA (1) CA2688766C (enExample)
CY (1) CY1115714T1 (enExample)
DK (1) DK2442832T3 (enExample)
ES (1) ES2521565T3 (enExample)
HR (1) HRP20141035T1 (enExample)
IL (1) IL216993A (enExample)
IN (1) IN2012DN00167A (enExample)
MX (1) MX2011013661A (enExample)
NZ (1) NZ577731A (enExample)
PL (1) PL2442832T3 (enExample)
PT (1) PT2442832E (enExample)
SI (1) SI2442832T1 (enExample)
SM (1) SMT201400165B (enExample)
WO (1) WO2010147484A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103990120B (zh) * 2008-04-01 2018-06-05 伊耐特免疫治疗有限公司 抗感染剂及其用途
EP3722808B1 (en) * 2010-10-25 2024-09-11 Biogen MA Inc. Methods for determining differences in alpha-4 integrin activity by correlating differences in svcam and/or smadcam levels
UY35790A (es) * 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
CA2926507A1 (en) * 2015-10-06 2017-04-06 Innate Immunotherapeutics Limited Compositions and methods for protection and/or repair of the nervous system
WO2017059486A1 (en) * 2015-10-06 2017-04-13 Innate Immunotherapeutics Limited Compositions and methods for the treatment of epilepsy
WO2017070731A1 (en) * 2015-10-28 2017-05-04 Innate Immunotherapeutics Limited Compositions and methods for the treatment of alzheimer's disease
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
AU2017319728B2 (en) 2016-08-31 2024-09-05 Mapi Pharma Ltd Depot systems comprising glatiramer acetate
IL316573A (en) 2017-03-26 2024-12-01 Mapi Pharma Ltd Storage systems containing glatiramer acetate for the treatment of multiple sclerosis
WO2019218079A1 (en) * 2018-05-18 2019-11-21 Universite Laval Use of nod2 agonist for the treatment, prophylaxis and/or delay of the onset of multiple sclerosis and alzheimer's disease
WO2020010221A1 (en) * 2018-07-03 2020-01-09 University Of Florida Research Foundation, Inc. Microparticle systems and their use for the treatment of multiple sclerosis
BR112022024966A2 (pt) * 2020-06-22 2023-01-03 Otivio As Métodos para tratar espasticidade usando composições antiespasmódicas e terapia de pressão negativa

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335017B1 (en) * 1996-10-10 2002-01-01 Probe International Inc. Compositions and methods for treating viral infections
WO2008150181A1 (en) * 2007-06-05 2008-12-11 Innate Therapeutics Limited Compositions and methods for treating anthrax exposure associated conditions
WO2008150182A1 (en) * 2007-06-05 2008-12-11 Innate Therapeutics Limited Compositions and methods for treatment of anthrax

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200700263A1 (ru) * 2004-07-01 2007-06-29 Кебенхавнс Университет Способ лечения и профилактики рассеянного склероза путём лечения лептоспирозной инфекции
WO2008070564A1 (en) 2006-12-01 2008-06-12 The Government Of The U.S.A, As Represented By The Secretary, Departmentof Health And Human Services Uses of muramyl dipeptide (mdp) for treating inflammation
JP2008251608A (ja) 2007-03-29 2008-10-16 Casio Comput Co Ltd 半導体装置およびその製造方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335017B1 (en) * 1996-10-10 2002-01-01 Probe International Inc. Compositions and methods for treating viral infections
WO2008150181A1 (en) * 2007-06-05 2008-12-11 Innate Therapeutics Limited Compositions and methods for treating anthrax exposure associated conditions
WO2008150182A1 (en) * 2007-06-05 2008-12-11 Innate Therapeutics Limited Compositions and methods for treatment of anthrax

Also Published As

Publication number Publication date
WO2010147484A1 (en) 2010-12-23
CY1115714T1 (el) 2017-01-25
JP5646617B2 (ja) 2014-12-24
ES2521565T3 (es) 2014-11-12
US20100317589A1 (en) 2010-12-16
IN2012DN00167A (enExample) 2015-04-17
AU2010260585A1 (en) 2012-01-19
EP2442832A1 (en) 2012-04-25
EP2442832A4 (en) 2013-07-03
US8389479B2 (en) 2013-03-05
SI2442832T1 (sl) 2014-12-31
JP2012530132A (ja) 2012-11-29
SMT201400165B (it) 2015-01-15
WO2010147484A8 (en) 2012-07-19
HK1167101A1 (en) 2013-02-01
BRPI1009606A2 (pt) 2016-10-11
CN102458476A (zh) 2012-05-16
EP2442832B1 (en) 2014-08-06
PT2442832E (pt) 2014-11-11
CA2688766C (en) 2015-06-30
DK2442832T3 (da) 2014-11-10
AU2010260585A8 (en) 2012-06-14
HRP20141035T1 (hr) 2014-12-19
IL216993A0 (en) 2012-02-29
CN102458476B (zh) 2014-08-20
MX2011013661A (es) 2012-05-22
PL2442832T3 (pl) 2015-01-30
CA2688766A1 (en) 2010-12-16
IL216993A (en) 2016-03-31
NZ577731A (en) 2010-08-27

Similar Documents

Publication Publication Date Title
EP2442832B1 (en) Compositions and methods for treatment of multiple sclerosis
JP6208235B2 (ja) 多発性硬化症治療のためのビオチンの使用
TW201119645A (en) Low frequency glatiramer acetate therapy
JP3806427B2 (ja) 新規鎮痛剤
Erman et al. A polysomnographic placebo-controlled evaluation of the efficacy and safety of eszopiclone relative to placebo and zolpidem in the treatment of primary insomnia
JP2008519847A (ja) 運動障害の治療方法
WO2014019268A1 (zh) 一种促进神经损伤修复的药物组合物及其应用
JP2001511121A (ja) コポリマー１の摂取又は吸入を通じての多発性硬化症の治療
JP2023549455A (ja) 脊髄性筋萎縮症を治療するための抗プロミオスタチン／抗潜在型ミオスタチン抗体の使用
US20220193051A1 (en) Treatment of migraine
JP2025514978A (ja) 脊髄性筋萎縮症を治療するためのミオスタチン阻害薬の使用
RU2701720C1 (ru) Комбинации пальмитоилэтаноламида для лечения хронической боли
KR20200101948A (ko) 신경계 질환 치료제
KR20170131543A (ko) 근위축성 측삭 경화증을 치료하기 위한 비오틴
Bocci The clinical application of ozonetherapy
JP2018519362A (ja) 炎症性疾患の予防または治療用ペプチド及びこの用途
EA028448B1 (ru) Способ снижения тяжести подобных гриппу симптомов, ассоциированных с лечением пациента с рассеянным склерозом, и набор для титрования для снижения тяжести подобных гриппу симптомов, ассоциированных с лечением пациента с рассеянным склерозом
RU2180591C2 (ru) Средство для лечения сексуальных дисфункций у мужчин
HK1167101B (en) Compositions and methods for treatment of multiple sclerosis
CN111803487B (zh) 银杏萜内酯在制备预防和/或治疗吉兰-巴雷综合征药物中的用途
US20060020037A1 (en) Tazarotenic acid and esters thereof for treating autism
JP2021530567A (ja) 安息香酸塩または安息香酸誘導体を含む、抗ｎ−メチル−ｄ−アスパラギン酸受容体脳炎を予防または治療するための医薬組成物
AU2009274022B2 (en) Compositions and methods for treating symptoms associated with menopause, hormonal variations and arthritis
CN109999179A (zh) 低剂量白介素2用于制备治疗阿尔茨海默病药物中的应用
Bubna IL-17 Antagonists

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 26, NO 2, PAGE(S) 255 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME INNATE IMMUNOTHERAPEUTICS LIMITED, APPLICATION NO. 2010260585, UNDER INID (22) CORRECT THE FILING DATE TO READ 16 JUNE 2010

TH Corrigenda

Free format text: IN VOL 26 , NO 2 , PAGE(S) 255 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME INNATE IMMUNOTHERAPEUTICS LIMITED, APPLICATION NO. 2010260585, UNDER INID (31) CORRECT THE NUMBER TO READ 577731

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired